Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.39 |
| ▸ | CHAT | P28329 | 2/20 | 0.36 |
| ▸ | EP300 | Q09472 | 3/20 | 0.34 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455992 | 0.93 | NAA50 (0.38) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL21996171 | 0.91 | NAA50 (0.40) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL23752163 | 0.88 | LPAR1 (0.43) | NAA50CHATENPP2LPAR1LPAR2 | |
| SCHEMBL23752166 | 0.88 | LPAR1 (0.43) | NAA50CHATENPP2LPAR1LPAR2 | |
| SCHEMBL30456357 | 0.86 | NAA50 (0.42) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL16693253 | 0.86 | NAA50 (0.48) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL21996236 | 0.85 | PTGS1 (0.49) | PTGS1KCNH2 | |
| SCHEMBL21996234 | 0.85 | PTGS1 (0.49) | PTGS1KCNH2 | |
| SCHEMBL11888083 | 0.85 | CHAT (0.43) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL21996188 | 0.84 | NAA50 (0.42) | NAA50CHATEP300AURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | NAA50 1148/4885CHAT 3110/4885EP300 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.